Eli Lilly and Co (HAM:LLY) Beneish M-Score: -1.67 (As of Jun. 27, 2026)


HAM:LLY Eli Lilly and Co HAM:LLY
98 GF Score
Price €1,039.40
GF Value €1,212.75
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Beneish M-Score?

Eli Lilly and Co HAM:LLY +3.96% 98 Beneish M-Score is -1.67 as of Jun. 27, 2026. GuruFocus rates HAM:LLY with a GF Score™ of 98/100 and a GF Value™ of €1,212.75 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 86.39% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.67 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Eli Lilly and Co's Beneish M-Score or its related term are showing as below:

HAM:LLY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.9   Med: -2.37   Max: -1.67
Current: -1.67

During the past 13 years, the highest Beneish M-Score of Eli Lilly and Co was -1.67. The lowest was -2.90. And the median was -2.37.


Eli Lilly and Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Beneish M-Score Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.36 -2.46 -1.91 -1.95 -1.74

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.77 -1.86 -1.80 -1.74 -1.67

HAM:LLY vs JNJ, ABBV, MRK: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Beneish M-Score falls into.


HAM:LLY
98GF Score
Eli Lilly and Co HAM:LLY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Eli Lilly and Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0365+0.528 * 0.9864+0.404 * 0.9102+0.892 * 1.3644+0.115 * 1.2717
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8609+4.679 * 0.068793-0.327 * 0.9026
=-1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €18,318 Mil.
Revenue was 17126.135 + 16475.368 + 14995.882 + 13488.526 = €62,086 Mil.
Gross Profit was 14032.03 + 13595.936 + 12432.81 + 11366.283 = €51,427 Mil.
Total Current Assets was €47,432 Mil.
Total Assets was €100,838 Mil.
Property, Plant and Equipment(Net PPE) was €22,957 Mil.
Depreciation, Depletion and Amortization(DDA) was €1,756 Mil.
Selling, General, & Admin. Expense(SGA) was €9,934 Mil.
Total Current Liabilities was €31,688 Mil.
Long-Term Debt & Capital Lease Obligation was €34,055 Mil.
Net Income was 6397.54 + 5668.596 + 4756.29 + 4907.653 = €21,730 Mil.
Non Operating Income was -802.72 + -1059.216 + -885.313 + -30.692 = €-2,778 Mil.
Cash Flow from Operations was 4613.045 + 2753.808 + 7528.187 + 2675.995 = €17,571 Mil.
Total Receivables was €12,953 Mil.
Revenue was 11774.325 + 12924.111 + 10306.629 + 10500.301 = €45,505 Mil.
Gross Profit was 9716.2 + 10628.768 + 8350.738 + 8484.185 = €37,180 Mil.
Total Current Assets was €38,167 Mil.
Total Assets was €82,685 Mil.
Property, Plant and Equipment(Net PPE) was €17,089 Mil.
Depreciation, Depletion and Amortization(DDA) was €1,697 Mil.
Selling, General, & Admin. Expense(SGA) was €8,457 Mil.
Total Current Liabilities was €27,813 Mil.
Long-Term Debt & Capital Lease Obligation was €31,912 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18318.105 / 62085.911) / (12952.96 / 45505.366)
=0.295044 / 0.284647
=1.0365

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(37179.891 / 45505.366) / (51427.059 / 62085.911)
=0.817044 / 0.828321
=0.9864

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (47432.275 + 22957.1) / 100838.24) / (1 - (38166.61 + 17088.542) / 82684.64)
=0.301958 / 0.331736
=0.9102

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=62085.911 / 45505.366
=1.3644

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1697.206 / (1697.206 + 17088.542)) / (1755.599 / (1755.599 + 22957.1))
=0.090345 / 0.07104
=1.2717

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9934.053 / 62085.911) / (8457.381 / 45505.366)
=0.160005 / 0.185855
=0.8609

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((34055.05 + 31688.41) / 100838.24) / ((31912.037 + 27812.992) / 82684.64)
=0.65197 / 0.722323
=0.9026

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(21730.079 - -2777.941 - 17571.035) / 100838.24
=0.068793

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Eli Lilly and Co has a M-score of -1.76 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.67 mean?
Eli Lilly and Co (HAM:LLY) has a Beneish M-Score of -1.67 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #787 out of 911 companies in the Drug Manufacturers industry, placing it in the top 86.4%.
Is Eli Lilly and Co's Beneish M-Score too high?
Eli Lilly and Co's current Beneish M-Score is -1.67. Based on the distribution chart, Eli Lilly and Co ranks #787 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Beneish M-Score compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #787 out of 911 companies for Beneish M-Score. This places Eli Lilly and Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Beneish M-Score is -1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,212.75, compared to a current price of €1,039.40 — trading 14.3% below its estimated fair value. The current Beneish M-Score is -1.67. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current Beneish M-Score is -1.67 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,039.40 is trading 14.3% below its estimated GF Value™ of €1,212.75. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • Beneish M-Score: -1.67
  • GF Value™: €1,212.75 vs. price of €1,039.40 (14.3% below fair value)
  • GF Score™: 98/100 with 6 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score

Get the complete analysis for HAM:LLY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,039.40
Price
€1,212.75
GF Value